The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Well, whichever way it went it's cleared now and we finished up +21% so it goes down as a positive in my book.
17:08:12 80.20 296,296 237.63k O
Happy weekend, everyone :-)
"We are now talking, potentially; prostate, breast, ovary, and uterine.
So; it could end up with one licensed indication. It could end up with 10. These are unlikely extremes, granted, but I don’t think that the 60M is going to be the expected potential final payment.
I also suspect that payments will start to come in stages before potential commercialization, and it may be that the product is sold on quite quickly for a decent wedge of that. I think that “commercialization” doesn’t necessarily mean they are running it to the end of Phase 3.
So, for me, I’m three feet in now, and I’ve fairly immediately taken the decision to retain 100% of my holding. US private finance looks to be the way forward for the new strategy, and I cannot overstate how impactful this is going to be in the next 1-2 years. It just doesn’t happen at our level.
GLA and have a good day.
PS – Oh – I forgot the royalties – could be very substantial. If you have 5-10% yearly on a blockbuster, you don’t need to raise, put it that way."
"Just to get in with some initial thoughts; I’ve just asked and believe Suzy will be doing an interview outlining the deal in more detail. This will be the start of more to come. It’s a solid proposition and a most welcome RNS for me.
These types of deal are becoming the norm, particularly in the US. It looks like VAL are now positioning themselves between academia and US corporate finance – nice.
Privately-backed finance development companies, who are awash with cash, are taking or funding candidates through Phase 2-3. Some float NASDAQ; some stay private. They have an excellent track record of pushing things through quickly and realising gains. They also won’t park this, like we’ve seen with other peer company tie-ups, which seem to take years (if at all) to realise.
I work with a number of them, so feel well-equipped to give my view on this, and I’m going to give it.
They will have scientists in this outfit, who I suspect will be working on the formulation and indications, to refresh the patent, and maximise any potential payments.
There is a massive upside here. It appears that Suzy has broken into US corporate finance. For VAL, that's probably a bigger ask than a pharma company, and they are so hard-nosed and purely finance-driven, they are almost better placed to do the heavy lifting.
This abodes EXTREMELY WELL for the new candidates, and I’d expect at least these sort of figures now for newer candidates at preclinical stage, without the “baggage” that we know has been associated with 201. I think we’ll now get more. Suzy and the team have finally proved that they can take something on, and sell it. Imagine what they are going to do with a shiny new product with 20 full years on the patent.
The initial payment is enough not to raise, and I’m fag-packeting that this will now be enough to sustain overheads. That’s what we needed, and I think we’re home and dry now with that one now. We can finally put it to bed.
Now – and this is where the material is to be digested:
It is a fee-per INDICATION. This product has not been passed over as purely a one-hit prostate drug. It has been out-licensed for ONCOLOGY.
This is unusual, in that I cannot tell you what any potential payments could be, in total.
Prostate cancer has a number of individual indications in and of itself. Some drugs are licensed for three indications in prostate cancer alone."
Anybody taking his comments seriously just needs to watch this (or any other of his) YouTube videos:
https://www.youtube.com/watch?v=_aiqVAi3PBU
And remember, folks: "Don't buy Kentucky Fried Chicken or McDonalds, buy Rambler Metals and Mining."
What's the plural of Guinness?
You also spelt merk incorrectly, twice.
But I ain't here to criticise.
This SP has sat in range of 0.06 to 0.07, except for a few peaks, for well over a year now; but the fundamentals have only grown stronger.
C'mon.
T H I N K B I G G E R